

# Mahrukh A Huseni

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1516956/publications.pdf>

Version: 2024-02-01

8  
papers

3,233  
citations

1163117

8  
h-index

1474206

9  
g-index

9  
all docs

9  
docs citations

9  
times ranked

5412  
citing authors

#	ARTICLE	IF	CITATIONS
1	Final Overall Survival and Molecular Analysis in IMmotion151, a Phase 3 Trial Comparing Atezolizumab Plus Bevacizumab vs Sunitinib in Patients With Previously Untreated Metastatic Renal Cell Carcinoma. JAMA Oncology, 2022, 8, 275.	7.1	75
2	Molecular determinants of response to PD-L1 blockade across tumor types. Nature Communications, 2021, 12, 3969.	12.8	79
3	Molecular Subsets in Renal Cancer Determine Outcome to Checkpoint and Angiogenesis Blockade. Cancer Cell, 2020, 38, 803-817.e4.	16.8	262
4	High systemic and tumor-associated IL-8 correlates with reduced clinical benefit of PD-L1 blockade. Nature Medicine, 2020, 26, 693-698.	30.7	250
5	Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial. Lancet, The, 2019, 393, 2404-2415.	13.7	778
6	Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. Nature Medicine, 2018, 24, 749-757.	30.7	900
7	CD8+ T cell infiltration in breast and colon cancer: A histologic and statistical analysis. PLoS ONE, 2018, 13, e0190158.	2.5	33
8	The Immunoreceptor TIGIT Regulates Antitumor and Antiviral CD8 + T Cell Effector Function. Cancer Cell, 2014, 26, 923-937.	16.8	851